The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Alvocidib followed by cytarabine and mitoxantrone in MCL-1–dependent R/R AML
In this interview, Joshua Zeidner, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the results of the Phase II Zella 201 study (NCT02520011) assessing the clinical response of alvocidib, in combination with cytarabine and mitoxantrone, in MCL-1–dependent, relapsed/refractory acute myeloid leukemia (AML) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Zeidner reveals that alvocidib given before cytarabine and mitoxantrone in MCL-1-dependent AML has clinical activity, particularly in those refractory to frontline therapy.
